Cargando…

CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin

CD30, a member of the TNF receptor superfamily, is selectively expressed on a subset of activated lymphocytes and on malignant cells of certain lymphomas, such as classical Hodgkin Lymphoma (cHL), where it activates critical bystander cells in the tumor microenvironment. Therefore, it is not surpris...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lobastova, Liudmila, Lettau, Marcus, Babatz, Felix, de Oliveira, Thais Dolzany, Nguyen, Phuong-Hien, Pauletti, Bianca Alves, Schauss, Astrid C., Dürkop, Horst, Janssen, Ottmar, Paes Leme, Adriana F., Hallek, Michael, Hansen, Hinrich P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cell and Developmental Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362802/ https://www.ncbi.nlm.nih.gov/pubmed/34395429 http://dx.doi.org/10.3389/fcell.2021.698503

Ejemplares similares

CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro
por: Hansen, Hinrich P., et al.
Publicado: (2016)

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

Brentuximab vedotin: targeting CD30 as standard in CTCL
por: Prince, H. Miles, et al.
Publicado: (2018)

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
por: Bartlett, Nancy L, et al.
Publicado: (2014)

Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
por: Scott, Lesley J.
Publicado: (2017)

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
por: Jagadeesh, Deepa, et al.
Publicado: (2022)

Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30(+) Lymphoma
por: Tudesq, Jean-Jacques, et al.
Publicado: (2017)

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30‐Expressing Hematologic Malignancies
por: Li, Hong, et al.
Publicado: (2017)

Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma
por: Hansen, Hinrich P., et al.
Publicado: (2020)

Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin
por: Kim, Hee Kyung, et al.
Publicado: (2015)

Oral mycosis fungoides with CD30(+) large cell transformation successfully treated with brentuximab vedotin
por: Goggins, Clare A., et al.
Publicado: (2019)

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas
por: Wagner, Sandro M., et al.
Publicado: (2020)

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia
por: Yang, Qing-Ming, et al.
Publicado: (2014)

Brentuximab vedotin exerts profound antiproliferative and pro‐apoptotic efficacy in CD30‐positive as well as cocultured CD30‐negative germ cell tumour cell lines
por: Schönberger, Stefan, et al.
Publicado: (2017)

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment
por: Zhao, Baiteng, et al.
Publicado: (2016)

A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
por: Sharman, Jeffrey P., et al.
Publicado: (2019)

Stromal cells support the survival of human primary chronic lymphocytic leukemia (CLL) cells through Lyn-driven extracellular vesicles
por: de Oliveira, Thaís Dolzany, et al.
Publicado: (2023)

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
por: Svoboda, Jakub, et al.
Publicado: (2020)

Role of stem cell transplant in CD30(+) PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2
por: Savage, Kerry J., et al.
Publicado: (2022)

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
por: Kim, Miso, et al.
Publicado: (2021)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
por: Gentille, Cesar, et al.
Publicado: (2022)

Successful Treatment of an Aggressive Adult T-cell Leukemia/Lymphoma with Strong CD30 Expression Using Brentuximab Vedotin as Combination and Maintenance Therapy
por: Baba, Yuta, et al.
Publicado: (2022)

Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
por: Kim, Youn H., et al.
Publicado: (2021)

Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study
por: Rausch, Christian, et al.
Publicado: (2022)

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma
por: Ogura, Michinori, et al.
Publicado: (2014)

Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature
por: Delacruz, Wilfred, et al.
Publicado: (2016)

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
por: Kim, Seok Jin, et al.
Publicado: (2020)

Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Stainthorpe, Angela, et al.
Publicado: (2020)

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
por: Horwitz, S., et al.
Publicado: (2022)

Primary Cutaneous CD30+/ALK- ALCL with Transition into sALCL: Favourable Response after Systemic Administration with Brentuximab Vedotin! Unique Presentation in a Bulgarian Patient!
por: Popova, Tanya Naskova, et al.
Publicado: (2018)

Brentuximab Vedotin
Publicado: (2012)

PB2351: TRIAL IN PROGRESS: A PHASE 2, MULTICENTRE STUDY OF BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IN FRONTLINE TREATMENT OF CHINESE PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMAS
por: Song, Yuqin, et al.
Publicado: (2023)

Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD)
por: Hong, Jennifer, et al.
Publicado: (2021)

Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility
por: Li, Bin, et al.
Publicado: (2017)

Characterization of CD30/CD30L(+) Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis
por: Barbieri, Alessandro, et al.
Publicado: (2015)

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients
por: Wang, D., et al.
Publicado: (2020)

Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
por: Tschernia, Nicholas P, et al.
Publicado: (2023)

Skin CD30(+) T cells and circulating levels of soluble CD30 are increased in patients with graft versus host disease
por: Amedei, Amedeo, et al.
Publicado: (2013)

Brentuximab vedotin induced uveitis
por: Therssen, Stijn, et al.
Publicado: (2022)

Diffuse skin hyperpigmentation in CD30+ lymphoproliferation
por: Prka, Zeljko, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ah11qfuamv7elg4p8e832gpp5u